PDCD1 and melanoma: One study held by [25] reported that ALKBH5 negatively influences the efficacy of anti-PD-1 therapy in melanoma by regulating the tumor-infiltration regulatory T cells (Tregs) and Myeloid-derived suppressor cells mediated by lactate metabolism.